Molecular Formula | C27H44O3 |
Molar Mass | 416.64 |
Density | 1.0362 (rough estimate) |
Melting Point | ~185°C |
Boling Point | 474.91°C (rough estimate) |
Specific Rotation(α) | D25 -69° (c = 0.5 in chloroform) |
pKa | 15.14±0.70(Predicted) |
Refractive Index | 1.4700 (estimate) |
In vitro study | Smilagenin (10 μM; 24 hours) increases SH-SY5Y cell survival compared with Aβ(25-35) intoxicated cells. Smilagenin (10 μM; 24 hours) increases neurotrophic factor (GDNF) and neurotrophic factor (BDNF) mRNA level by promoting CREB phosphorylation in 1-methyl-4-phenylpyridimium (MPP + ) treated SH-SY5Y cells. Cell Viability Assay Cell Line: SH-SY5Y cells Concentration: 10 μM Incubation Time: 24 hours Result: Elevated the SH-SY5Y cell viability. RT-PCR Cell Line: SH-SY5Y cells Concentration: 10 μM Incubation Time: 24 hours Result: Increased GDNF and BDNF transcription. |
In vivo study | Smilagenin (intragastric administration; 10 or 26 mg/kg, once daily; 60 days) prevents the impairment of dopaminergic neurons in chronic MPTP/probenecid-induced mouse model. Animal Model: MPTP/probenecid-induced mouse model Dosage: 10 or 26 mg/kg Administration: Intragastric administration; 10 or 26 mg/kg; once daily; 60 days Result: Ameliorated locomotor ability of MPTP/probenecid-lesioned mice. |
WGK Germany | 3 |
FLUKA BRAND F CODES | 10 |
biological activity | Smilagenin (SMI) is a fat-soluble small molecule steroidal sapogenin from Anemarrhena asphodela Rhizoma anemarrhenae and Pelargonium Radix asparagi, widely used in the study of chronic neurodegenerative diseases. Smilagenin (SMI) improves memory in aged rats by increasing the density of muscarinic receptor subtype 1 (M1)-receptors. Smilagenin (SMI) attenuates Aβ (25-35)-induced neurodegeneration by stimulating gene expression of brain-derived neurotrophic factor and can be used in the study of AD. |
target | Human Endogenous Metabolite |
in vitro study | Smilagenin (10 μM; 24 hours) increases SH-SY5Y cell survival compared with Aβ(25-35) intoxicated cells. Smilagenin (10 μM; 24 hours) increases neurotrophic factor (GDNF) and neurotrophic factor (BDNF) mRNA level by promoting CREB phosphorylation in 1-methyl-4-phenylpyridimium (MPP ) treated SH-SY5Y cells. Cell Viability Assay Cell Line: SH-SY5Y cells Concentration: 10 μM Incubation Time: 24 hours Result: Elevated the SH-SY5Y cell viability. RT-PCR Cell Line: SH-SY5Y cells Concentration: 10 μM Incubation Time: 24 hours Result: increased GDNF and BDNF transcription. |
Cell Line: | SH-SY5Y cells SH-SY5Y cells |
Concentration: | 10 μM 10 μM |
Incubation Time: | 24 hours 24 hours |
Result: | Elevated the SH-SY5Y cell viability. Increased GDNF and BDNF transcription. Ameliorated locomotor ability of MPTP/probenecid-lesioned mice. |
in vivo study | Smilagenin (intragastric administration; 10 or 26 mg/kg, once daily; 60 days) prevents the impairment of dopaminergic neurons in chronic MPTP/probenecid-induced mouse model. Animal Model: MPTP/probenecid-induced mouse model Dosage: 10 or 26 mg/kg Administration: Intragastric administration; 10 or 26 mg/kg; 10 or 26 mg/kg; once daily; 60 days Result: Ameliorated locomotor ability of MPTP/probenecid-lesioned mice. |
Animal Model: | MPTP/probenecid-induced mouse model |
Dosage: | 10 or 26 mg/kg |
Administration: | Intragastric administration; 10 or 26 mg/kg; once daily; 60 days |